Location: Jackson, TN; Orlando, FL
Indication: Atopic Dermatitis and Healthy Controls
Sponsor: Precision Biospecimen Solutions, Inc.
PI: Dafnis Carranza, MD; Christopher Chappel, MD
Intervention/Treatment: Biospecimen collection
Ages: 18+
Criteria:
- Subjects with a documented diagnosis of Atopic Dermatitis
- Diagnosis must be within one year
- Healthy subjects without a diagnosis of Atopic Dermatitis or generalized dermatology conditions
Compensation: You may be compensated for your time and participation
Location: Orlando, FL
Indication: Urticaria
Sponsor: Teva Pharmaceuticals USA
PI: Christopher Chappel, MD
Intervention/Treatment: TEV-45779 and XOLAIR®️️️
Age: 18-75
Criteria:
• Has diagnosis of CIU refractory to H1 antihistamines for ≥3 months
• Does NOT have chronic urticaria with clearly defined underlying etiology
• Does NOT have other skin disease associated with itch
Compensation: You may be compensated for your time and participation
About: The purpose of the study is to compare the efficacy, pharmacokinetics, pharmacodynamics, safety, tolerability, and immunogenicity of TEV-45779 compared to XOLAIR in patients with Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) who remain symptomatic on H1 antihistamine treatment.
